Epicrispr Biotechnologies secured $90 million in a Series C round after sharing early data for EPI-321, an epigenetic editing approach targeting facioscapulohumeral muscular dystrophy (FSHD). The funding is intended to push the program toward pivotal clinical studies after the company’s ongoing Phase I/II trial and first-in-human enrollment progress. FSHD is driven by inappropriate expression of the DUX4 gene, and Epicrispr designed EPI-321 to durably suppress pathological DUX4 expression using a single AAV vector without permanently altering DNA sequence. The company said it plans to use the proceeds primarily for pivotal development, including registrational study preparation. Epicrispr also framed the Series C as a shift from platform demonstration to late-stage execution, citing proof-of-principle data and “first-in-human” clinical momentum. The company highlighted its Gene Expression Modulation System (GEMS) platform as enabling additional indications where DUX4-like misexpression may be addressed.